keep relying on our company’s reputation
to stand out – not in the Brave New World of Data! We need to be smart, strategic and
tech-savvy in order to reach new heights in precision, productivity and patient centricity
Data has become the new currency of productivity and ROI, and the pharmaceutical industry must face the challenges it brings head on, or risk losing the value story both in R&D and patient relationships. We need to move past the challenge of integrating unstructured data sets and collaborate on multiple levels with other departments and organisations to create a real world evidence framework for our product development through effective data utilisation.
This September, industry leaders from key pharma companies like Janssen, Merck, BERG Health, AstraZeneca, Celgene & GSK will be sharing their insights into the role of data analytics, discussing tangible method for data optimisation, and translating this into real world strategies for your company.
Are you an industry innovator trying to advance your company’s data utilisation? Are you intent on maximising your analytical capabilities and value, but unsure of your next steps? We all know that Data Analytics, or ‘Big Data’ is not new to the industry, but this year’s Data Analytics for Pharma Development Forum will ensure that you are at the forefront of innovative industry discussion and process excellence strategies!
2018 Featured Speakers
Director, Data Science, IKU in EMEA
Director of Architecture and Software Innovation
Global Head Technology and Architecture for Global Drug Development
Senior Director, AI & Machine Learning
Group Data Privacy Lead – GDPR
Vectura Group plc.
Practical Big Data Analytics: Hands-on Techniques to Implement Enterprise Analytics and Machine Learning Using Hadoop, Spark, NoSQL and R
What Others Have to Say
"It’s not just about the volume of data, it’s the complexity of data that we are challenged by."
"Delivered top bang for the buck, and more! Superb."
"If this is your field, all the big players are there."
"Extremely valuable as my company is setting out on an joint Info Governance and e-discovery programme."